Xinma Bio is committed to the R&D and production of biological products. Zhejiang Pharmaceutical announced today that its subsidiary, Xinma Biology, has announced its B round capital increase to introduce Advanced Manufacturing Industry Investment Fund Phase II (Limited Partnership), Li’an Xinshao Co., Ltd., Suzhou Lirun Equity Investment Center (Limited Partnership), Runtu Co., Ltd. (002440) Ten strategic investors, including 10 strategic investors, intend to increase the capital of the target company with a total capital increase of 400 million yuan or equivalent US dollars, and subscribe for the new registered capital of the target company of 3.626 million yuan (the remaining capital increase is included in the target company. The company’s capital reserve), and obtained about 12.9454% equity of the target company after the capital increase.
This article is reproduced from: https://www.itjuzi.com/investevent/13325126
This site is for inclusion only, and the copyright belongs to the original author.